Momenta Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Momenta Pharmaceuticals Inc. (MNTA)

Q4 2011 Earnings Call

February 9, 2012 10:00 am ET

Executives

Beverly Holley - Director, IR

Craig Wheeler - President & CEO

Rick Shea - SVP & CFO

Analysts

Sumant Kulkarni - Bank of America

Duane Nash - Wedbush Securities

Alan Sonnenfeld - Sanford Bernstein

Ritu Baral - Canaccord

Ami Fadia - UBS

Joseph Schwartz - Leerink Swann

Jami Rubin - Goldman Sachs

Imran Babar - Cowen & Co

Presentation

Operator

Compare to:
Previous Statements by MNTA
» Momenta Pharmaceuticals CEO Hosts Investor Conference Call to Discuss Follow-On Biologics Collaboration with Baxter (Transcript)
» Momenta Pharmaceuticals' Management Presents at Deutsche Bank BioFEST 2011 - Event Transcript
» Momenta Pharmaceuticals' CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Momenta Pharmaceuticals CEO Discusses Q2 2011 Results - Earnings Call Transcript

Good day ladies and gentlemen and welcome to the Momenta Pharmaceuticals fourth quarter and yearend 2011 earnings conference call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder this call maybe recorded. I would now like to introduce your host for today's conference, Beverly Holley, Director of Investor Relations. Ma’am, you may begin.

Beverly Holley

Thank you and good morning. I want to welcome all of you to Momenta’s conference call to discuss financial results for the fourth quarter and full-year 2011 and provide a corporate update. With me on the call today with prepared remarks are Craig Wheeler, President and Chief Executive Officer, and Rick Shea, Chief Financial Officer. Following our remarks, we’ll open the call to questions.

Before we begin, I’d like to mention that our call today will contain forward-looking statements about management’s future expectations, beliefs, plans and prospects. These forward-looking statement include comments about our enoxaparin sodium injection commercial prospects and our generic competitors’ prospects for approval and commercialization; our generic Copaxone program, ANDA review and patent litigation expectations; and our other project development plans and expectations, including our future development, partnering and commercialization potential for our development programs.